Treatment of chronic granulomatous disease-associated fistulising colitis with vedolizumab

J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1748-1749. doi: 10.1016/j.jaip.2017.07.035. Epub 2017 Sep 14.

Authors

Nicholas Campbell¹, Hugo Chapdelaine²

Affiliations

¹ Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
² Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. Electronic address: hugo.chapdelaine.chum@ssss.gouv.qc.ca.

PMID: 28919373
DOI: 10.1016/j.jaip.2017.07.035

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Colitis / drug therapy*
Digestive System Fistula / drug therapy*
Granulomatous Disease, Chronic / drug therapy*
Humans
Immunotherapy / methods*
Male
Middle Aged
Recurrence
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / immunology

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
vedolizumab